Success will increasingly depend on connecting robust clinical data with compliant claims, labeling strategies, lifecycle evidence generation, and market-specific regulatory pathways
Studies have shown that tirzepatide can lead to an average weight loss of up to 17.8% after 72 weeks of treatment
Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort affect a significant proportion of patients, though symptoms typically improve over time as the body adjusts to the medication
Patches might sound like a great idea, but right now thats all they are, an idea without proof
Increasing focus on cardiometabolic benefits, including reduced cardiovascular risk, alongside weight management
So, for all the women and the lovely men caring for their loved ones, this section is an important one - Convenience and Lifestyle Fit This is where the biggest difference lies between the pill and the injection